FDA EIR - Janssen Biotech Inc. - September 24, 2024

An FDA inspection was conducted at Janssen Biotech, Inc. in Horsham, PA, from September 16 to September 24, 2024. The comprehensive review evaluated various critical areas of the company's operations, particularly concerning its management of clinical trials and adherence to regulatory standards. Key areas of focus included the selection and oversight of clinical investigators, detailed monitoring procedures, robust quality assurance activities, and the processes for safety and adverse event reporting. The inspection also scrutinized the functions of the data monitoring committee, data collection and handling practices, electronic records and signatures, and the management of investigational products. Additionally, the firm's record custody, retention policies, and financial disclosure processes were reviewed. Throughout the diligent assessment, FDA investigators found no objectionable conditions or major anomalies that could impact data reliability. Significantly, no FDA Form 483, which details inspectional observations, was issued. This indicates that no regulatory violations or deficiencies requiring corrective action were identified during this inspection. As a result, no specific regulatory framework violations or mandatory actions were stipulated for Janssen Biotech, Inc. based on this assignment.